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Abstract 
Objectives: Academic institutions routinely 
require in-house review of pathology prior to 
treatment. However, it is unclear if pathology 
review is beneficial for the management of 
patients referred for cervical intraepithelial 
neoplasia (CIN). This study aims to determine if 
review of outside pathology for CIN at an 
academic medical center resulted in a change in 
the treatment plan and the associated cost for 
pathology review. 
Methods: A retrospective chart review of 
patients referred for treatment of CIN, including 
review of outside cytology and histology was 
performed from January 1 to December 31, 
2007 after obtaining IRB approval. Data was 
analyzed to determine whether pathology 
diagnosis was changed from the outside facility 
interpretation; classified as minor if there was no 
change in clinical management and major if 
there was a change in treatment as a result of 
the internal review. Demographic and pathology 
information was collected from electronic 
medical records. Billing information was 
collected from the finance department. Data 
were analyzed using descriptive statistics. 
Results: Seventy-eight patients were identified 
of which 54 had outside pathology slides 
available for pathology review. Eleven had a 
minor change in the pathology diagnosis (20%). 
None of the changes in pathology diagnosis 
resulted in a change in treatment plan (major). 
The total pathology review charge was $14,679 
for the 54 patients, with an average charge per 
patient of $272. Nine of the cases were charged 
twice to reflect the opinion of two separate 
pathologists (internal consultation). Of the 54 
patients, 23 (43%) had state supported 
insurance, 24 (44%) had private insurance, and 
7 (13%) were self-pay. A total of $12,969.29 was 
not covered/paid (88% of all charges) and thus 
absorbed by the institution.             
Conclusion: Mandatory review of outside 
pathology is a common practice. However, it 
may not be beneficial in all clinical situations. 
While this pathology review for CIN resulted in 
minor changes for 20% of patients referred to 
our academic/tertiary institution, it did not affect 
any treatment recommendations. Pathology 
review did increase the cost burden to the 
institution and the patient. 
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Introduction 
It is estimated that over 300,000 women 
in the United States have a diagnosis of 
cervical intraepithelial neoplasia (CIN) II-
III, the precursor to cervical cancer.1 The 
annual incidence of CIN II-III is 
estimated at 1.5 per 1000 women 
annually.2-3 Overall, the risk of 
progression of CIN II lesions to cancer is 
around 5% and the risk of progression 
to CIN III is 20%.4 A diagnosis of CIN III 
however, carries a 12% risk of 
progression to cancer. Another factor to 
consider is the cost of treatment. In one 
study, the costs per episode of care 
were higher for CIN II-III than CIN I 
($1,634 vs $1,084) with an estimated 
annual burden per 1,000 US women of 
$1,803 for CIN II-III.2  
Patients with CIN II-III lesions are often 
referred to tertiary/academic care 
centers for treatment. A survey of 126 
hospitals found 50% required internal 
review of outside slide material before 
surgical intervention, while 75% of 
academic institutions required in-house 
review of outside pathology.5 The goal 
of this secondary review was reduction 
in error by redundancy. A 21 month 
review at The Johns Hopkins Hospital 
found the rate of major diagnostic 
disagreement ranged from 1 to 3% 
across all organ sites.6 Reviews of 
gynecologic oncology patients have 
found 4.7 to 6.8% of cases resulted in a 
change in diagnosis that had major 
prognostic implications.7-8 Regarding 
CIN II-III specifically, most of the 
variability in diagnosis seems to stem 
from the diagnosis of CIN II. This is due 
to the heterogeneity of CIN II lesions 
and discrepancies between different 
pathologists.9 This is clinically important 
because the threshold for treatment is 
CIN II, with exceptions for management 
in younger women.10-11  
The largest study to identify variability in 
pathology between clinical pathologists 
and academic pathologists was a 
multicenter randomized control trial, the 
ASCUS-LSIL Triage Study (ALTS).12 
They found that interpretation of CIN I 
by the clinical center was corroborated 
by the quality control group in only 
42.6% biopsies.12 Alternatively, an equal 
proportion of originally diagnosed CIN I 
biopsies (41.0%) were interpreted as 
negative by the pathology quality control 
group. Indeed, interpathologist variability 
regarding the diagnosis of CIN has been 
identified in multiple studies.13  
The purpose of this study was to 
determine if review of outside pathology 
at an academic medical center resulted 
in a difference in the diagnosis and 
subsequent treatment plan for women 
referred with CIN, and explore the cost 
associated with the secondary 
pathology review. 
Materials and Methods 
Participants of this retrospective cohort 
review included all women age 18 years 
of age or older who were referred to a 
single academic/tertiary colposcopy 
clinic for evaluation and treatment of 
cervical high-grade dysplasia, including 
CIN II and CIN III from January 1, 2007 
to December 31, 2007. University of 
Iowa Institutional Review Board 
approval was obtained. Exclusion 
criteria included missing outside 
material (pathology slides) available for 
pathology review. 
Demographic characteristics including 
age, parity, contraception use, 
menopausal status, tobacco use, as well 
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as the external pathology diagnosis and 
internal pathology review were 
abstracted from electronic patient 
records. Non-cervical gynecologic 
pathology was excluded, including 
vulvar and vaginal pap smears as well 
as endometrial biopsies. The patient 
payer status, amount charged for 
pathology review of outside material, 
and amount covered by insurance was 
collected from the billing department. 
The cost for pathology review was in 
2007 dollars (actual cost during the time 
period of the retrospective review). 
Data were analyzed using descriptive 
statistics including frequency, means 
and percentages. Diagnostic 
discrepancies were categorized as 
minor or major as described by 
others.7,14 Minor discrepancies did not 
impact clinical care and major 
discrepancies resulted in a change in 
treatment.7,14  
Table 1: Patient demographic characteristics 
Patient Characteristics % Respondents 
Median Age (years): 21 
(Range 18-78) 
 
   
Parity: 0 49% 
 1 or greater 31% 
 Unknown 20% 
   
Menopause status: Pre: 94% 
 Post: 6% 
   
Tobacco Use: Yes 26% 
 No 52% 
 Unknown 22% 
   
Contraception: Pregnant 6% 
 None 11% 
 Unknown 9% 
 DepoProvera 22% 
 OCP 38% 
 Condoms 2% 
 Surgical 6% 
 Menopause 6% 
 
Results  
A total of 78 patients were referred for 
treatment of CIN II-III from outside our 
institution, of which 54 had complete 
information (including outside pathology 
slides for review) available for analysis. 
The median age of patients in the study 
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was 21 years with a range of 18-78 
years. Forty-nine percent were 
nulliparous and 94% were 
premenopausal. Fifty-two percent 
denied tobacco use. The most 
commonly reported form of birth control 
was oral contraceptives (38%) followed 
by medroxyprogesterone injection 
(22%). (Table 1)  
The internal pathology review resulted in 
a change of diagnosis for 11 of the 54 
cases (20%). Of which 5 of 11 (45%) 
were upgraded from CIN II to CIN III and 
6 of 11 (55%) were downgraded from 
CIN III to CIN II. None of the pathology 
reviews resulted in a change in 
treatment plan. –  the recommendation 
for treatment was based on treatment of 
high grade lesions (encompassing CIN 
II/III) and the pathology reviews did not 
change from high grade to low grade or 
vice-versa. 
The total amount charged for the 
internal pathology review was $14,679 
with the average charge per patient 
$272 ($228-470). Nine patients were 
charged between $456-470 because 
two separate pathologists reviewed the 
outside slides (review with internal 
consultation). The insurance payers 
were evenly dispersed between Iowa 
Care (state form of Medicaid) and 
private insurance (43% vs 44%) with an 
average cost of $6500 billed for the 
entire visit including pathology review, 
colposcopy, and treatment if it was 
performed.  
Regarding the pathology review charge, 
the total amount captured by insurance 
was $1,709 which left the remaining 
amount of $12,969 (88%) uncovered, 
with the hospital absorbing the cost. 
Furthermore, among the uncovered 
charges, six patients did not present for 
evaluation and treatment despite referral 
and pathology review, comprising $1722 
of the uncovered charges.   
Discussion 
The introduction of cervical screening 
with cytology has significantly reduced 
morbidity and mortality related to 
cervical cancer in developed nations.15 
This is due to the detection of both pre-
invasive changes as well as invasive 
cancer at earlier stages which allows for 
earlier treatment.15 When abnormal 
cytology and histology is identified, 
patients may be referred to another 
facility for further evaluation and 
management. There is limited data to 
support or refute whether review of 
outside pathology for diagnostic 
confirmation is necessary or cost 
effective especially for CIN. One could 
argue that review of outside pathology 
prior to treatment would potentially 
guard against needless treatment of 
CIN. This is especially important in 
younger populations that desire fertility. 
In a study published in the Journal of the 
American Medical Society, treatment for 
CIN was not associated with increased 
risk of total preterm delivery or 
spontaneous preterm delivery but did 
reveal an increased risk of preterm 
premature rupture of membranes.16 As 
noted previously, this is clinically 
relevant as CIN II is often the threshold 
for treatment and may present as a 
transient process especially in younger 
women.11-13  
While our study demonstrated that up to 
20% of cytology and pathology 
diagnoses were changed on review, 
none of the changes resulted in a 
modification of the treatment plan. A 
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study recently published in the American 
Journal of Surgical Pathology found that 
only 38.2% of CIN I and 38.0% of 
community-diagnosed CIN II were 
conﬁrmed by expert review.13 
Community-diagnosed CIN I and CIN II 
were downgraded respectively to CIN I 
and upgraded to CIN II on panel review 
35.1% and 32.4% of the time. They did 
find that more CIN II were upgraded to 
CIN III (53.3%) than CIN III being 
downgraded to CIN II (32.6%).13 
However, comparison of CIN II found 
the percent of the population diagnosed 
as CIN II by the community was only 
slightly greater than that estimated by 
expert review (11.9% vs. 10.7%, 
P=0.024).13 While heterogeneity in 
pathology diagnosis is reported, Chan et 
al. evaluated types of specimens 
reviewed among 569 pathology 
specimens at a tertiary care center and 
concluded cervical and vaginal smears 
do not benefit from pathology review.14 
Cytological specimens accounted for no 
major discrepancies.14  
Our results did reveal significant cost 
added to each review with up to 88% of 
the charges unpaid. This adds to the 
enormous cost of human papillomavirus 
(HPV) related disease including CIN. In 
2010, the overall direct cost burden of 
diagnosis and management of HPV-
associated disease was estimated to be 
8.0 billion dollars.17 Approximately $6.6 
billion (82.3%) was for screening and 
associated follow-up.17  
Our study is limited by the time period 
data were collected from. Given newer 
screening guidelines published in 2012, 
this same study conducted more 
recently might yield different results. Our 
study is subject to limitations in 
methodology including single institution 
retrospective cohort study with a small 
sample size. An attempt was made to 
extract data effectively from electronic 
medical records. To limit selection bias, 
all patients with outside specimens were 
included. The small sample size is a 
limitation in that major discrepancies 
affecting management may have been 
identified if all patients referred for 
treatment had specimens available for 
review (54 of 78 had pathology material 
available for review). Further studies are 
needed to validate the results and to 
determine if there is a cost reduction 
achieved by avoiding a secondary 
pathology review for CIN. Additionally, 
given recent implementation of 
molecular pathology techniques to aid in 
the diagnosis of CIN II, it would be 
interesting to see if new techniques 
improve diagnostic accuracy and 
consistency among pathologists.  
Based on the findings of this study, 
mandatory review of outside pathology 
prior to treatment of cervical 
intraepithelial neoplasia at a referral 
center may not necessarily be of value 
and should possibly be left to the clinical 
judgment of the treating physician. 
References 
1. Saslow D, Castle PE, Cox JT, Davey 
DD, Einstein MH, Ferris DG, Goldie SJ, 
Harper DM, Kinney W, Moscicki AB, 
Noller KL, Wheeler CM, Ades T, 
Andrews KS, Doroshenk MK, Kahn KG, 
Schmidt C, Shafey O, Smith RA, 
Partridge EE; Gynecologic Cancer 
Advisory Group, Garcia F. American 
Cancer Society Guideline for human 
papillomavirus (HPV) vaccine use to 
prevent cervical cancer and its 
precursors. CA Cancer J Clin. 2007 Jan-
Feb;57(1):7-28. 
https://doi.org/10.3322/canjclin.57.1.7  
PubMed PMID: 17237032. 
Proceedings in Obstetrics and Gynecology, 2018;8(2):1 
 
 
Review of outside pathology  6 
2. Henk HJ, Insinga RP, Singhal PK, 
Darkow T. Incidence and costs of 
cervical intraepithelial neoplasia in a US 
commercially insured population. J Low 
Genit Tract Dis. 2010 Jan;14(1):29-36. 
https://doi.org/10.1097/LGT.0b013e318
1ac05e9 PubMed PMID:  20040833. 
3. Insinga RP, Glass AG, Rush BB. 
Diagnoses and outcomes in cervical 
cancer screening: a population-based 
study. Am J Obstet Gynecol. 2004 
Jul;191(1):105-13. 
https://doi.org/10.1016/j.ajog.2004.01.04
3 PubMed PMID: 15295350. 
4. Nasiell K, Nasiell M, Vaćlavinková V. 
Behavior of moderate cervical dysplasia  
during long-term follow-up. Obstet 
Gynecol. 1983 May;61(5):609-14. 
PubMed PMID: 6835614. 
5. Gupta D, Layfield LJ. Prevalence of 
inter-institutional anatomic pathology 
slide review: a survey of current 
practice. Am J Surg Pathol. 2000 
Feb;24(2):280-4. 
https://doi.org/10.1097/00000478-
200002000-00014 PubMed PMID: 
10680896. 
6. Kronz JD, Westra WH, Epstein JI. 
Mandatory second opinion surgical 
pathology at a large referral hospital. 
Cancer. 1999 Dec 1;86(11):2426-35. 
https://doi.org/10.1002/(SICI)1097-
0142(19991201)86:11<2426::AID-
CNCR34>3.0.CO;2-3  PubMed PMID: 
10590387. 
7. Eskander RN, Baruah J, Nayak R, 
Brueseke T, Ji T, Wardeh R, Tewari KS. 
Outside slide review in gynecologic 
oncology: impact on patient care and 
treatment. Int J Gynecol Pathol. 2013 
May;32(3):293-8. 
https://doi.org/10.1097/PGP.0b013e318
26739c4 PubMed PMID: 23518913. 
8. Selman AE, Niemann TH, Fowler JM, 
Copeland LJ. Quality assurance of 
second opinion pathology in gynecologic 
oncology. Obstet Gynecol. 1999 
Aug;94(2):302-6. 
https://doi.org/10.1016/S0029-
7844(99)00318-X  PubMed PMID: 
10432147. 
9. Dalla Palma P, Giorgi Rossi P, Collina 
G, Buccoliero AM, Ghiringhello B, Gilioli 
E, Onnis GL, Aldovini D, Galanti G, 
Casadei G, Aldi M, Gomes VV, Giubilato 
P, Ronco G; NTCC Pathology Group. 
The reproducibility of CIN diagnoses 
among different pathologists: data from 
histology reviews from a multicenter 
randomized study. Am J Clin Pathol. 
2009 Jul;132(1):125-32. 
https://doi.org/10.1309/AJCPBRK7D1YI
UWFP  PubMed PMID: 19864243. 
10. Kinney W, Hunt WC, Dinkelspiel H, 
Robertson M, Cuzick J, Wheeler CM; 
New Mexico HPV Pap Registry Steering 
Committee. Cervical excisional 
treatment of young women: a 
population-based study. Gynecol Oncol. 
2014 Mar;132(3):628-35. 
https://doi.org/10.1016/j.ygyno.2013.12.
037 Epub 2014 Jan 4. PubMed PMID: 
24395062; PubMed  Central PMCID: 
PMC3992337. 
11. Massad LS, Einstein MH, Huh WK, 
Katki HA, Kinney WK, Schiffman M, 
Solomon D, Wentzensen N, Lawson 
HW; 2012 ASCCP Consensus 
Guidelines Conference. 2012 updated 
consensus guidelines for the 
management of abnormal cervical 
cancer screening tests and cancer 
precursors. J Low Genit Tract Dis. 2013 
Apr;17(5 Suppl 1):S1-S27. 
https://doi.org/10.1097/LGT.0b013e318
287d329 Erratum in: J Low Genit Tract 
Dis.  2013 Jul;17(3):367. PubMed PMID: 
23519301. 
Proceedings in Obstetrics and Gynecology, 2018;8(2):1 
 
 
Review of outside pathology  7 
12. Stoler MH, Schiffman M; Atypical 
Squamous Cells of Undetermined 
Significance-Low-grade Squamous 
Intraepithelial Lesion Triage Study 
(ALTS) Group. Interobserver 
reproducibility of cervical cytologic and 
histologic interpretations: realistic 
estimates from the ASCUS-LSIL Triage 
Study. JAMA. 2001 Mar 
21;285(11):1500-5. 
https://doi.org/10.1001/jama.285.11.150
0 PubMed PMID: 11255427. 
13. Stoler MH, Ronnett BM, Joste NE, Hunt 
WC, Cuzick J, Wheeler CM; New 
Mexico HPV Pap Registry Steering 
Committee. The Interpretive Variability 
of Cervical Biopsies and Its Relationship 
to HPV Status. Am J Surg Pathol. 2015 
Jun;39(6):729-36. 
https://doi.org/10.1097/PAS.000000000
0000381  PubMed PMID: 25602796; 
PubMed Central PMCID: PMC4428379. 
14. Chan YM, Cheung AN, Cheng DK, Ng 
TY, Ngan HY, Wong LC. Pathology slide 
review in gynecologic oncology: routine 
or selective? Gynecol Oncol. 1999 
Nov;75(2):267-71. 
https://doi.org/10.1006/gyno.1999.5567  
PubMed PMID: 10525384. 
15. Saslow D, Solomon D, Lawson HW, 
Killackey M, Kulasingam SL, Cain J, 
Garcia FA, Moriarty AT, Waxman AG, 
Wilbur DC, Wentzensen N, Downs LS 
Jr, Spitzer M, Moscicki AB, Franco EL, 
Stoler MH, Schiffman M, Castle PE, 
Myers ER; American Cancer Society; 
American Society for Colposcopy and 
Cervical Pathology; American Society 
for Clinical Pathology. American Cancer 
Society, American Society for 
Colposcopy and Cervical Pathology, 
and American Society for Clinical 
Pathology screening guidelines for the 
prevention and early detection of 
cervical cancer. Am J Clin Pathol. 2012 
Apr;137(4):516-42. 
https://doi.org/10.1309/AJCPTGD94EV
RSJCG PubMed PMID: 22431528. 
16. Sadler L, Saftlas A, Wang W, Exeter M, 
Whittaker J, McCowan L. Treatment for 
cervical intraepithelial neoplasia and risk 
of preterm delivery. JAMA. 2004 May 
5;291(17):2100-6. 
https://doi.org/10.1001/jama.291.17.210
0 PubMed PMID: 15126438. 
17. Chesson HW, Ekwueme DU, Saraiya M, 
Watson M, Lowy DR, Markowitz LE. 
Estimates of the annual direct medical 
costs of the prevention and treatment of 
disease associated with human 
papillomavirus in the United States. 
Vaccine. 2012 Sep 14;30(42):6016-9. 
https://doi.org/10.1016/j.vaccine.2012.0
7.056 Epub 2012 Aug 4. PubMed PMID: 
22867718. 
 
 
